




**OXFORD
GLOBAL**

Biomarkers Europe 2023

+ Co-located with Precision Oncology Europe 2023
& Targets & Cell Types in Immuno-Oncology 2023

14 - 15 November 2023 | Berlin, Germany



Day 1 Track 1: Biomarker Analysis – Multiplex Technology Application & Translational Research

- Application of spatial transcriptomics & Multiplex Profiling
- Challenges of single vs multiplexed biomarker validation
- Panel discussion: Benchmarking and translation of Biomarkers- Lessons Learnt
- Multiplexed assays for the successful scale up of translational research
- Application of multiplex biomarker approaches to accelerate drug discovery and development
- Flow cytometry as a platform for biomarker discovery and clinical validation
- Developing multi-parameter flow cytometry tools
- Overcoming: Challenges of multiplexed flow cytometry technologies application

Day 1 Track 2: Biomarkers Approaches in Drug Discovery & Translational Sciences

- Qualification of biomarkers for translational studies
- Efficacy and PK/PD biomarkers in drug development
- Case studies in biomarker discovery and validation
- The role of safety and efficacy biomarkers
- Assay development & validation
- Translational biomarkers from preclinical to clinical phase studies
- Case studies in biomarker validation in: Oncology & Immuno therapy

Day 2: Emerging Approaches for Biomarker Analysis

- Regulation of Biomarker Analysis – what can be translated in the clinic
- Using Sampling methods to analyze Biomarkers - Benefits and Challenges
- Approach for Identifying Drug Sensitivity Biomarkers Across Diverse Data Types for Patient Selection
- Bioanalysis Strategies & Approaches
- Biomarker Methods and Data Tools For Analysis (AI and Algorithms- understandable and plausible?)
- Optimising clinical development programs through effective assay validation
- Integrating predictive biomarker assays

Meet Senior Decision Makers

350+ VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

Flow Cytometry
Enabling Technologies
Analysis/Bioanalysis

Assay Development
Preclinical Development
Translation

Multiplex Technologies
Biomarker Validation

Biomarker Validation
Clinical Development
Biomarker

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Cytometry
Multiplex Tools
Immunoassays

Biomarker Analysis
Biomarker Validation
Assay Development

Cytometry
Multiplex Tools
Immunoassays

Biomarker Analysis
Biomarker Validation
Assay Development

2nd Biomarker Europe Congress Benefits to Attending

- ✓ **Hear from and meet with over 350 leading biomarker figures working in discovery & development and biomarker analysis**
- ✓ **Acquire knowledge about how biomarker approaches are utilized in drug discovery and translational sciences** for targeted oncology and immuno-related therapies.
- ✓ **Explore how companies accelerate timelines and reduce risk in drug development.** Approaches to biomarker development include targeted biomarker discovery, multi-omic biomarker discovery, real-time biomarker monitoring, and companion diagnostic development in oncology & Immunological disorders
- ✓ **Gain insights into emerging bioanalysis approaches,** assay development, and what can be translated in the clinic
- ✓ **The event is co-located with Precision Oncology Congress and Targets & Cell Types in Immuno-Oncology Congress**

Key 2023 Speakers:



Priyank Patel,
Senior Scientist
Boehringer
Ingelheim




Francesca Bosisio,
Head of the MILAN
Multiplexing Unit,
Laboratory For
Translational
Cell And Tissue
Research, KU Leuven



Rob Slack, Vice
President & Head
of Pharmacology,
Galecto

For booking details & registration fees please refer to the last page or visit:

<https://www.oxfordglobal.co.uk/biomarkers-immuno-series-us/>



Day 1: Molecular Analysis, Multi-Cancer Early Detection And Testing, Companion Diagnostic Development

- Molecular characterization of tumour for targeted therapy selection
- Biomarker and companion diagnostic discovery and development
- Multi-Cancer Early Detection, Advanced Diagnostics, And Population Screening
- Multi-Cancer Early Detection And Minimal Residual Disease Testing
- The Use Of Digital Pathology And Image Analysis In Tissue-Based Cancer Biomarker Validation

Day 2 Biomarkers for Clinical Development and Personalised Patient Treatment

- Bench to bedside and back again
- Digital pathology on biomarker patient profiling
- Integration of trials, labs and data sciences to drive faster clinical development
- Genomics-enabled clinical trials for tailored cancer drug development
- Includes a workshop on latest technologies in testing, biomarker and patient monitoring
- Liquid Biopsy Biomarker Development and Implementation for Precision Oncology

Benefits to Attending

- ✓ Bringing together experts In Oncology And Cancer Care, Clinical Research, And Drug Development To Explore application in diagnosis, stratification & prognosis in oncology, and advancing personalized treatment to improve patient outcomes
- ✓ 200+ attendees and 15+ presentations
- ✓ Showcasing the latest technologies and clinical studies in multi-cancer early detection and minimal residual disease testing
- ✓ Learn from molecular characterization of tumour for targeted therapy selection
- ✓ Gain insights into biomarker and companion diagnostic discovery and development
- ✓ Benefit from Digital Pathology And Image Analysis In Tissue-Based Cancer Biomarker Validation
- ✓ Explore genomics-enabled clinical trials for tailored cancer drug development
- ✓ **This event is co-located with the Targets & Cell Types in Immuno-Oncology Congress**


Key 2023 Speakers:



Philip Beer, Chief Scientific Officer, Step Pharma



Anna Maria Lara Coenen-Stass, Associate Director, Clinical Biomarkers & Companion Diagnostics, Merck KGaA



Gilles Erb, Global Scientific Director Integrated Medicine / PHC, Roche

Meet Senior Decision Makers

Over 150 VPs, Directors and Senior Managers from leading pharmaceutical organizations, biotech companies and academic institutions will attend the event. Delegate job titles include:

Preclinical Development

Clinical Development

Precision Medicine Translation

Biomarker Validation
Companion Diagnostics

Molecular testing

Early Detection

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Clinical Development /Trial Solutions/CROs

Precision Medicine Solutions
Multiplexing/flow cytometry
Residual Disease Testing

Digital Pathology & Imaging, AI
Biomarker Analysis

Genomic testing companies
Companion Diagnostics

Biomarker Europe Confirmed & Reserved Speakers 2023 Include

- Sari Pesonen, Chief Scientific Officer, Valo Therapeutics
- Rob Slack, Vice President & Head of Pharmacology, Galecto
- Emmanuel Valentin, Vice President, Translational Medicine, ImCheck Therapeutics
- Matthew Davis, Senior Director, Molecular Biology and Sequencing, Gritstone Bio
- Ken Chang, Senior Director, Translational Biomarkers and Precision Medicine, Daiichi Sankyo
- Guillaume Desachy, Statistical Science Director, Late-Stage Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca.
- Stephanie Traub, Associate Director, Bioanalytical Scientific Manager, Translational Biomarkers & Bioanalysis, UCB
- Iris Kolder, Associate Director, Translational & Clinical Data Science, Genmab
- Mario Richter, Head of Global Regulated Bioanalysis and Biomarker Support, AbbVie.
- Brian Lockhart, Global Head of Companion Diagnostics, Servier
- Nolwen Guigal-Stephan, Head of Clinical Biomarkers, Servier
- Eike Staub, Head of Oncology Data Science, Merck KGaA
- Akanksha Goyal, Senior Scientist and Principal Investigator (GLP), Research and Clinical Bioanalytics (RCB), CSL Behring Innovation GmbH
- Debora Souza Da Costa, Biosample Operations Specialist, Roche Pharma Research & Early Development (pRED) Pharmaceutical
- Anna Frömming, Medical Science & Translational Research Manager (Immuno)-Oncology, NOXXON Pharma
- Priyank Patel, Senior Scientist, Boehringer Ingelheim
- Wei Zheng, Group Leader, National Center for Advancing Translational Sciences, National Institutes of Health
- Francesca Maria Bosisio, Head of the MILAN Multiplexing Unit, Laboratory For Translational Cell And Tissue Research, KU Leuven
- Frederik De Smet, Head of the MILAN Multiplexing Unit, Laboratory For Translational Cell And Tissue Research, KU Leuven
- Alain van Gool, Professor of Personalized Healthcare, Radboud University Medical Center
- Arcangelo Liso, Professor of Hematology and Head of the Laboratory of Hematology, University of Foggia
- Marc Goldfinger, Clinical Biomarker Lead, GSK (*reserved*)
- Ronen Sadeh, Founder & CEO, Senseera Health (*reserved*)

Precision Oncology Europe Confirmed & Reserved Speakers 2023 Include:

- Anna Maria Lara Coenen-Stass, Associate Director, Clinical Biomarkers & Companion Diagnostics, Merck KGaA
- Gilles Erb, Global Scientific Director Integrated Molecular Medicine / PHC, Roche
- Philip Beer, Chief Scientific Officer, Step Pharma
- Thomas H. Jensen, Co-Founder, Allarity Therapeutics
- Svetlana Mukhina, CDx Global Regulatory Lead, Director Global Regulatory Affairs, CDx, Merck KGaA
- Ian D Waddell, CEO, Nodus Oncology Limited
- Nina Eissler, Associate Director, Translational Medicine, Affibody AG
- Priscila Teixeira, Senior Principal Scientist, Roche
- Peter Horvath, Director of the Institute of Biochemistry, Biological Research Centre, BRC, Szeged, Hungary, and the High-Content Analysis Facility, HELMI, University of Helsinki
- Salvatore Piscuoglio, Group Leader & Principal Investigator, University of Basel
- Jonathan Krell, Clinical Senior Lecturer, Imperial College London
- Twan Lammers, Professor, Head of Department Nanomedicine and Theranostics, Aachen University
- Christophe Le Tourneau, Medical Oncologist, Institut Curie, and Professor of Medicine, Versailles-Saint-Quentin-en-Yvelines Universit
- Ravid Straussman, Professor, Weizmann Institute, Israel
- Ed Schuurin, Full Professor in Molecular Oncological Pathology, Senior Clinical Scientist in Molecular Pathology, Head of the Laboratory for Molecular Pathology, Department of Pathology, University Medical Center Groningen
- Kjetil Taskén, Head, Institute for Cancer Research, Group Leader, ICR Dept. of Cancer Immunology, Director, OUH Centre for Precision Cancer Medicine, Division for Cancer Medicine, OUH Comprehensive Cancer Centre, Oslo University Hospital

Biomarkers and Precision Oncology Europe Congress 2023 & Targets & Cell Types in Immuno-Oncology Congress Sponsors:

Gold Sponsors



Silver Sponsors:





Bronze Sponsors:



Networking & Programme Sponsors:



Biomarker and Precision Oncology Europe Congress – Day One | 14th November 2023, Berlin

08:15	Oxford Global's Welcome Address & Chairperson's Opening Address		
	Biomarker Europe Congress		Precision Oncology Europe Congress
	Track 1: Biomarker Analysis – Multiplex Technology Application & Translational Research	Track 2: Biomarker Development for Drug Discovery & Translational Research	Track 3: Molecular Analysis, Multi-Cancer Early Detection And Testing, Companion Diagnostic Development
08.30	Keynote Address: Challenges Of Single Vs Multiplexed Biomarker Validation CONFIRMED: Stephanie Traub, Associate Director, Bioanalytical Scientific Manager, Translational Biomarkers & Bioanalysis, UCB	Developing Translational PD Biomarkers In Idiopathic Pulmonary Fibrosis CONFIRMED: Rob Slack, Vice President & Head of Pharmacology, Galecto	Biomarker And Companion Diagnostic Discovery And Development CONFIRMED: Anna Maria Lara Coenen-Stass, Associate Director, Clinical Biomarkers & Companion Diagnostics, Merck KGaA
08.55	Multiplex Biomarker Approaches To Immuno-Oncology CONFIRMED: Frederik De Smet, Head of the MILAN Multiplexing Unit, Laboratory For Translational Cell And Tissue Research, KU Leuven Francesca Maria Bosisio, Head of the MILAN Multiplexing Unit, Laboratory For Translational Cell And Tissue Research, KU Leuven	Translational Biomarkers In EVICTION Study Of ICT01 An Anti-BTN3A Monoclonal Antibody Activating Vg9Vd2 T Cells CONFIRMED: Emmanuel Valentin, VP, Translational Medicine, ImCheck Therapeutics	Liquid Biopsy Biomarker Development and Implementation for Precision Oncology CONFIRMED: Gilles Erb, Global Scientific Director Integrated Molecular Medicine / PHC, Roche
09.20	Gold Solution Provider Presentation 	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk	Silver Solution Provider Presentation 
09.50	Biomarker Development Using Patient iPS Cells For Rare Disease Drug Discovery CONFIRMED: Wei Zheng, Group Leader, National Center for Advancing Translational Sciences, National Institutes of Health	QuANTUM-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival <ul style="list-style-type: none"> A lower level of MRD post-induction in the QuANTUM-First trial was associated with longer survival, irrespective of treatment arm The addition of Quizartinib to 7+3 is associated with a reduction in MRD by the end of induction Irrespective of pre allo-HCT MRD status, longer survival was observed in those treated with Quizartinib versus placebo The long-term survival benefits conferred by Quizartinib in the QuANTUM-First trial may in part derive from an early and deep reduction of the FLT3-ITD+ leukemia burden CONFIRMED: Ken Chang, Senior Director, Translational Biomarkers, Precision Medicine, Daiichi Sankyo	Next Generation Image Analysis Solutions - Towards Image-Based Diagnostics CONFIRMED: Peter Horvath, Director of the Institute of Biochemistry, Biological Research Centre, BRC, Szeged, Hungary, and the High-Content Analysis Facility, HELMI, University of Helsinki
10.15	Morning Break and 1-2-1 meetings x 4		


Biomarker and Precision Oncology Europe – Day One | 14th November 2023, Berlin

Biomarker Europe Congress		Precision Oncology Europe Congress	
	Track 1: Biomarker Analysis – Multiplex Technology Application & Translational Research	Track 2: Biomarker Development for Drug Discovery & Translational Research	Track 3: Molecular Analysis, Multi-Cancer Early Detection And Testing, Companion Diagnostic Development
11.35	Solution Provider Presentation 	Solution Provider Presentation 	Solution Provider Presentation 
12.05	Drug Discovery & Application Of Spatial Biology Crohn’s Disease CONFIRMED: Priyank Patel, Senior Scientist, Boehringer Ingelheim Pharmaceuticals	CTNA And How It Can Be Applied In Clinical Trials CONFIRMED: Nolwen Guigal-Stephan, Head of Clinical Biomarkers, Servier	Regulatory Considerations For Companion Diagnostics: US And EU Perspective <ul style="list-style-type: none"> • Precision Medicine: Drug diagnostic co-development • CDx regulatory framework in the US • Changes in the EU CDx regulatory landscape: The impact of IVDR CONFIRMED: Svetlana Mukhina, CDx Global Regulatory Lead, Director Global Regulatory Affairs, CDx, Merck KGaA
12.30	Multi Omics Data-Based Innovations In Translational Biomarker Research CONFIRMED: Alain van Gool, Professor of Personalized Healthcare, Radboud University Medical Center	Biomarker Development for Drug Discovery & Translational Research CONFIRMED: Iris Kolder, Associate Director, Early Translational Research, Genmab	Biomarkers in Target Validation – Identifying Patient Population CONFIRMED: Ian D Waddell, CEO, Nodus Oncology Limited
12.55	Lunch and 1-2-1 meetings x3		
13.55	Solution Provider Presentation 	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk
14.25	Disease Monitoring with Comprehensive Genomics Provides Evidence of Mechanism of Action and Immune Evasion in Patients Receiving an Individualized Neoantigen Cancer Vaccine CONFIRMED: Matthew Davis, Senior Director, Molecular Biology and Sequencing, Gritstone Bio	Tissue- Based Biomarker Discovery In IHC CONFIRMED: Anna Frömning, Medical Science & Translational Science Research Manager (Immuno-Oncology), NOXXON Pharma	Use Of PET Imaging For Oncology Companion Diagnostic Development CONFIRMED: Nina Eissler, Associate Director, Translational Medicine, Affibody AG
14.50	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk
15.20	Afternoon Break and 1-2-1 meetings x3		


Biomarker and Precision Oncology Europe – Day One | 14th November 2023, Berlin

	Biomarker Europe Congress	Precision Oncology Europe Congress
	Track 1: Biomarker Analysis – Multiplex Technology Application & Translational Research	Track 3: Molecular Analysis, Multi-Cancer Early Detection And Testing, Companion Diagnostic Development
16.20	Biomarker Discovery and Tools For Analysis CONFIRMED: Arcangelo Liso, Professor of Hematology and Head of the Laboratory of Hematology, University of Foggia	Panel Discussion: Early Detection, Imaging, Screening And Minimal Residual Disease Testing PANELLISTS: Ed Schuurig, Full Professor in Molecular Oncological Pathology, Senior Clinical Scientist in Molecular Pathology, Head of the Laboratory for Molecular Pathology, University Medical Center Groningen Alain van Gool, Professor of Personalized Healthcare, Radboud University Medical Center
16.45	Panel Discussion: Utilising Flow Cytometry In Translational, And Clinical Research: Challenges & Opportunities MODERATOR: Arcangelo Liso, Professor of Hematology and Head of the Laboratory of Hematology, University of Foggia	Detection Of Clinically Actionable Mutations In NSCLC For Early Detection, Diagnosis And Monitoring Tumor Response Using Plasma-Derived Cell Free DNA CONFIRMED: Ed Schuurig, Full Professor in Molecular Oncological Pathology, Senior Clinical Scientist in Molecular Pathology, Head of the Laboratory for Molecular Pathology, Department of Pathology (HPC EA10), University Medical Center, Groningen
17.10	Closing Keynote: Implementing Genomic Based Medicine <ul style="list-style-type: none"> • What are the current barriers to the delivery of genomic medicine into routine healthcare settings? • How can mainstreaming of genomics accelerate drug development and biomarker discover? CONFIRMED: Philip Beer, Chief Scientific Officer, Step Pharma	
17.35	End of Day 1 and Networking Drinks	
18.15	<p align="center"> Networking Dinner <i>Private invite-only hosted dinner.</i> For Sponsorship Opportunities please contact sponsorship@oxfordglobal.co.uk </p>	


Biomarker and Precision Oncology Europe – Day Two | 15th November 2023, Berlin

	Biomarker Europe Congress	Precision Oncology Europe Congress
	Track 1: Emerging Technologies for Biomarker Analysis and Biomarker Assay Development	Track 2: Biomarkers For Clinical Development And Personalised Patient Treatment
08.55	<p>Round Discussion 1- Challenges And Opportunities Of Developing Multiplexed IHC Moderator: Anna Frömning, Medical Science & Translational Science Research Manager (Immuno-Oncology), NOXXON Pharma (reserved)</p> <p>Round Discussion 2- Do Biomarkers Need To Biologically Plausible Moderator: Emmanuel Valentin, VP, Translational Medicine, ImCheck Therapeutics</p> <p>Round Discussion 3- Biomarkers As End Points In Clinical Trials – Moderator: Guillaume Desachy, Statistical Science Director, Late-Stage Development, Respiratory & Immunology, AstraZeneca</p> <p>Round Discussion 4- What Makes A Good Companion Diagnostic Moderator: Nina Eissler, Associate Director, Translational Medicine, Affibody AG</p> <p>Round Discussion 5 – Regulation Of Biomarkers Invitation to: Steve Lee, ABPI</p> <p>Round Discussion 6- AI And Algorithms- Do They Need To Be Understandable – Round Discussion 7 - Biobanking and Biomarker Development</p>	
09.25	<p>Track Keynote Address: Precision Medicine In Action: Designing A Trial With A Biomarker Threshold Optimization</p> <ul style="list-style-type: none"> • The challenge: Designing an early phase clinical trial answering multiple scientific questions, including a biomarker threshold (BT) optimization • The solution: A seamless study supported by the Health Authorities, with a central precision medicine approach • The unexpected: Our will to accelerate the development of this compound led us to revisit the study design • The outcome: A streamlined trial effectively addressing the original scientific questions, including the BD optimization <p>CONFIRMED: Guillaume Desachy, Statistical Science Director, Late-Stage Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca</p>	<p>Track Keynote Address: Building National Precision Medicine Trial In Norway</p> <p>CONFIRMED: Kjetil Taskén, Head, Institute for Cancer Research, Group Leader, ICR Dept. of Cancer Immunology, Director, OUH Centre for Precision Cancer Medicine, Division for Cancer Medicine, OUH Comprehensive Cancer Centre, Oslo University Hospital</p>
09.50	<p align="center">Gold or Silver Solution Provider Presentation</p> <p align="center">  </p>	<p align="center">Gold or Silver Solution Provider Presentation</p> <p align="center">For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk</p>
10.20	<p>Novel Platforms For Oncolytic Virus-based Cancer Immunotherapy</p> <p>CONFIRMED: Sari Pesonen, Chief Scientific Officer, Valo Therapeutics</p>	<p>Precision Tools for Cancer Nanomedicine - Biomarkers for Patient Stratification</p> <ul style="list-style-type: none"> •Nanomedicine formulations, such as liposomes and micelles, are employed to improve tumour-targeted drug delivery and anticancer therapy. •The tumour accumulation of nanomedicines occurs via the Enhanced Permeability and Retention (EPR) effect, which is highly variable in patients, both inter- and intra-individually. •Patient stratification via imaging or biopsy biomarkers is needed to improve cancer nanomedicine performance and clinical translation <p>CONFIRMED: Twan Lammers, Professor, Head of Department Nanomedicine and Theranostics, Aachen University</p>

Biomarker and Precision Oncology Europe – Day Two | 15th November 2023, Berlin

	Biomarker Europe Congress	Precision Oncology Europe Congress
	Track 1: Emerging Technologies for Biomarker Analysis and Biomarker Assay Development	Track 2: Biomarkers For Clinical Development And Personalised Patient Treatment
10.45	Morning Refreshment and 1-2-1 Meetings x4	
12.05	Biomarker Assay Development And Therapeutic Applications CONFIRMED: Mario Richter, Head of Global Regulated Bioanalysis and Biomarker Support, AbbVie	Precision Medicine and Clinical Trials - How We Adapt Trials To Patient Requirements And Needs CONFIRMED: Christophe Le Tourneau, Senior Medical Oncologist, Institut Curie and Professor of Medicine, Versailles-Saint-Quentin-en-Yvelines University
12.30	Solution Provider Presentation 	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk
13:00	Emerging Technologies For Companion Diagnostic Development CONFIRMED: Brian Lockhart, Global Head of Companion Diagnostics, Servier	Workshop: Prediction of Drug Response Using an Ex Vivo Organ Culture (EVOC) on Oncology Patients, Clinical Trial Development and Patient Testing – Presentation 1: (15 minutes) Using Ex-Vivo Organ Culture Technology For Precision Anti-Cancer Therapy •Multiple components in the complex ecosystem of the tumor microenvironment can affect the response of cancer cells to anti-cancer therapy. •Ex vivo organ culture technology can functionally test the sensitivity of cancer cells to anti-cancer therapy while retaining the 3D, native, patient-specific tumor microenvironment. •Recent technological advances allow better culturing of human tumors ex vivo, thus paving the way for clinical use of EVOC technology as a predictive biomarker. CONFIRMED: Ravid Straussman, Professor Weizmann Institute, Israel Presentation 2: Trial Development & Clinical Utility Of Testing (15 minutes) CONFIRMED: Jonathan Krell, Clinical Senior Lecturer, Imperial College London
13.25	Integration Of Trials, Labs And Data Sciences To Drive Faster Clinical Development CONFIRMED: Debora Souza Da Costa, Biosample Operations Specialist, Roche Pharma Research & Early Development (pRED) Pharmaceutical	CONFIRMED: Ravid Straussman, Professor Weizmann Institute, Israel Presentation 2: Trial Development & Clinical Utility Of Testing (15 minutes) CONFIRMED: Jonathan Krell, Clinical Senior Lecturer, Imperial College London
13.50	Lunch and 1-2-1 meetings x3	

Biomarker and Precision Oncology Europe – Day Two | 15th November 2023, Berlin

	Biomarker Europe Congress	Precision Oncology Europe Congress
	Track 1: Emerging Technologies for Biomarker Analysis and Biomarker Assay Development	Track 2: Biomarkers For Clinical Development And Personalised Patient Treatment
14.50	Solution Provider Presentation 	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk
15.20	Panel Discussion - Optimising Bioassays For New Therapeutic Modalities <ul style="list-style-type: none"> • Gene Vectors • Car T Cells PANELLISTS: Matthew Davis, Senior Director, Molecular Biology and Sequencing, Gritstone Bio Invitation to: Senior Representative, Abbvie	Workshop Continues: Workshop Moderator: Jonathan Krell, Clinical Senior Lecturer, Imperial College London Panel Discussion: (40 minutes) PANELLISTS: Anna Maria Lara Coenen-Stass, Associate Director, Merck KGaA Thomas H. Jensen, Co-Founder, Allarity Therapeutics Priscila Teixeira, Senior Principal Scientist, Roche
15.45	Panel Discussion - Reducing Bias in Data Analysis <ul style="list-style-type: none"> • How do we identify different cell types/ Cell classification • Defining cell types based on functional rather than phenotypic classification 	
16.10	Development And Fit-For Purpose Validation Of A Modified And Drug-Tolerant Immunogenicity Assay Our work underlines the importance of developing assays which are not only functional and validated but fit-for-purpose for the context-of-use which takes into account the characteristics and requirements of the individual study. A modified biotin-drug extraction and acid dissociation (BEAD) immunogenicity assay was developed to detect anti-drug-antibodies (ADA) against the human anti-FXIIa monoclonal antibody drug, Garadacimab (previously called CSL312). Multiple strategies were tested to optimize the signal-to-background ratio, assay sensitivity and the drug tolerance. The modified BEAD assay was found to be highly drug tolerant with a sensitivity in line with current FDA regulatory guidelines. The assay was validated for use in a repeat-dose animal safety study and showed an acceptable intra-assay precision and robustness but a lower inter-assay precision. In-study sample analysis confirmed that the assay was fit-for-purpose for the context-of-use in the nonclinical study. The strategies employed here to modify and optimize the BEAD assay may be transferred to other species, ADA assay formats and biologic drugs to generate accurate, robust and most importantly meaningful results. CONFIRMED: Akanksha Goyal, Senior Scientist and Principal Investigator (GLP), Research and Clinical Bioanalytics (RCB), CSL Behring Innovation GmbH Integration Of Trials, Labs And Data Sciences To Drive Faster Clinical Development	
16.35	Afternoon Break	

Biomarker and Precision Oncology Europe – Day Two | 15th November 2023, Berlin

	Biomarker Europe Congress	Precision Oncology Europe Congress
	Track 1: Emerging Technologies for Biomarker Analysis and Biomarker Assay Development	Track 2: Biomarkers For Clinical Development And Personalised Patient Treatment
16.50	Novel Biomarkers For Small Cell Lung Carcinoma RESERVED: Marc Goldfinger, Clinical Biomarker Lead, GSK	A Gene Expression Based Biomarker for Predicting Response to Treatment with Dovitinib and Ixabepilone CONFIRMED: Thomas H. Jensen, Co-Founder, Allarity Therapeutics
17.15	Title TBA CONFIRMED: Eike Staub, Head of Oncology Data Science, Merck KGaA	Augmenting Precision Oncology Using Tumor-Derived 3D Models <ul style="list-style-type: none"> • Co-culture of organoids and cells in the microenvironment is an asset for drug discovery and investigation into the mechanisms of drug response. • PDOs can be used to rationally design clinical trials to reduce failure rates. • The use of organoids for clinical management holds great potential. CONFIRMED: Salvatore Piscuoglio, Principal Investigator, University of Basel
17.40	End of Congress	